Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT. (Q39579138)

From Wikidata

Jump to navigation Jump to search

scientific article published on 8 March 2011

Language	Label	Description	Also known as
English	Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT.	scientific article published on 8 March 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT. (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

neuroendocrine tumor

1 reference

based on heuristic

inferred from title

Irvin M. Modlin

6

object named as

Irvin M Modlin

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

author name string

Bernhard Svejda

1

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Mark Kidd

2

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Alexander Kazberouk

3

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Ben Lawrence

4

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Roswitha Pfragner

5

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

language of work or name

0 references

publication date

8 March 2011

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

117

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

18

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

4141-4154

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Gastroenteropancreatic neuroendocrine tumours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26011

21 January 2018

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26011

21 January 2018

Current status of gastrointestinal carcinoids

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26011

21 January 2018

Defining the role of mTOR in cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26011

21 January 2018

Will mTOR inhibitors make it as cancer drugs?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26011

21 January 2018

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26011

21 January 2018

Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26011

21 January 2018

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26011

21 January 2018

GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26011

21 January 2018

Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26011

21 January 2018

Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26011

21 January 2018

Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26011

21 January 2018

Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26011

21 January 2018

Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26011

21 January 2018

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26011

21 January 2018

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26011

21 January 2018

Targeting mTOR with rapamycin: one dose does not fit all

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26011

21 January 2018

The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26011

21 January 2018

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26011

21 January 2018

Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26011

21 January 2018

Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26011

21 January 2018

Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26011

21 January 2018

Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26011

21 January 2018

Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26011

21 January 2018

Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26011

21 January 2018

The functional characterization of normal and neoplastic human enterochromaffin cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26011

21 January 2018

Further delineation of the continuous human neoplastic enterochromaffin cell line, KRJ-I, and the inhibitory effects of lanreotide and rapamycin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26011

21 January 2018

Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26011

21 January 2018

Inhibition of proliferation of small intestinal and bronchopulmonary neuroendocrine cell lines by using peptide analogs targeting receptors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26011

21 January 2018

The 5-HT(2B) receptor plays a key regulatory role in both neuroendocrine tumor cell proliferation and the modulation of the fibroblast component of the neoplastic microenvironment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26011

21 January 2018

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26011

21 January 2018

WST-1-based cell cytotoxicity assay as a substitute for MTT-based assay for rapid detection of toxigenic Bacillus species using CHO cell line

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26011

21 January 2018

Small bowel carcinoid (enterochromaffin cell) neoplasia exhibits transforming growth factor-beta1-mediated regulatory abnormalities including up-regulation of C-Myc and MTA1.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26011

21 January 2018

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26011

21 January 2018

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26011

21 January 2018

Autoregulatory effects of serotonin on proliferation and signaling pathways in lung and small intestine neuroendocrine tumor cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26011

21 January 2018

Microsatellite instability and gene mutations in transforming growth factor-beta type II receptor are absent in small bowel carcinoid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26011

7 January 2021

based on heuristic

inferred from DOI database lookup

GeneChip, geNorm, and gastrointestinal tumors: novel reference genes for real-time PCR

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26011

7 January 2021

based on heuristic

inferred from DOI database lookup

Presence of IGF-I in human midgut carcinoid tumours--an autocrine regulator of carcinoid tumour growth?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26011

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.26011

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39579138&oldid=2220959705"